Peking University People's Hospital
北京大学人民医院
Listed for 28 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Peking University People's Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌2 papers led
- Hepatocellular carcinoma肝细胞癌24 papers led1 open trial led
- Stomach cancer胃癌21 papers led3 open trials led
- Retinoblastoma视网膜母细胞瘤0 papers led
- Chordoma脊索瘤6 papers led
- Osteosarcoma骨肉瘤42 papers led2 open trials led
- Gastrointestinal stromal tumour胃肠道间质瘤8 papers led2 open trials led
- Ewing sarcoma尤文肉瘤7 papers led2 open trials led
- Multiple myeloma多发性骨髓瘤19 papers led5 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病19 papers led4 open trials led
- Aplastic anaemia再生障碍性贫血29 papers led3 open trials led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症7 papers led1 open trial led
- Haemophilia A血友病 A0 papers led1 open trial led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜4 papers led2 open trials led
- Fanconi anaemia范可尼贫血2 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led1 open trial led
- IgG4-related diseaseIgG4相关性疾病12 papers led1 open trial led
- Myasthenia gravis重症肌无力3 papers led
- Takayasu arteritis大动脉炎1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
- Behçet disease白塞病5 papers led1 open trial led
- IgA nephropathyIgA 肾病0 papers led
- Gaucher disease戈谢病0 papers led
- Osteogenesis imperfecta成骨不全症2 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎7 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
- Congenital diaphragmatic hernia先天性膈疝0 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Neuroblastoma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Niemann–Pick disease type C, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 2 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.07%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)8
- Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial.
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 24 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.
17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingComparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07010588
Age 18 years to 75 years (registered criteria)
Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led24
- Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study.
- Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma.
- Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma.
- Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.
- Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients.
- AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma.
- Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications.
- Clinical potential of serum prostaglandin A2 as a novel diagnostic biomarker for hepatocellular cancer.
- All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines.
- Methodological challenges in studying immune-suppressive neutrophils in HCC models.
- For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
- Augmentation of hepatocellular carcinoma malignancy by annexin A5 through modulation of invasion and angiogenesis.
- NDRG1 facilitates self-renewal of liver cancer stem cells by preventing EpCAM ubiquitination.
- A signature based on NKG2D ligands to predict the recurrence of hepatocellular carcinoma after radical resection.
- The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
- Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.
- Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
- Outcome of near-infrared fluorescence-navigated pulmonary metastasectomy for hepatocellular carcinoma.
- Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment.
- The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.
- Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease.
- Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer.
- Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma.
- Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status4
- Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Cancer
Stomach cancer
胃癌Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07857668
Age 20 years to 80 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingMCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06748690
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingNeoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07018063
Age 16 years to 45 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingTEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07714980
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led21
- Endoscopic semi-blunt dissection technique is safe and effective for treating gastric submucosal tumors from the muscularis propria.
- Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy.
- CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.
- CXCR2P1 enhances the response of gastric cancer to PD-1 inhibitors through increasing the immune infiltration of tumors.
- Extramural venous invasion in gastric cancer: 9.4T magnetic resonance imaging assessment and circular RNA functional analysis.
- Sintilimab and Cardiovascular Toxicity.
- Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration.
- Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer.
- Safety and efficacy of vagus nerve-preserving distal gastrectomy for early gastric cancer: A systematic review and meta-analysis.
- Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.
- Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.
- Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer.
- Pathological diagnosis, differential diagnosis and origin investigation of easily misdiagnosed adult gastric duplication cysts.
- Uncut Roux-en-Y might reduce the rate of reflux gastritis after radical distal gastrectomy: An evidence mapping from a systematic review.
- Long noncoding RNA ZNFX1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPR1N1.
- Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.
- Development and evaluation of a ceMDCT-based preoperative risk stratification model to predict disease-free survival after radical surgery in patients with gastric cancer.
- A signature of 24 aging‑related gene pairs predict overall survival in gastric cancer.
- CT-detected extramural venous invasion-related gene signature for the overall survival prediction in patients with gastric cancer.
- Diagnosis of gastric lesions through a deep convolutional neural network.
- Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?
Chinese-language papers (not in the count)5
- [Research progress on peritoneal metastasis of gastric cancer in the era of immunotherapy].
- [Endoscopic ultrasonographic features of submucosal lesions of upper digestive tract suspected gastrointestinal stromal tumors and their correlation with progression and pathological risk grade of the lesions].
- [Updates on the molecular classification of gastric cancer].
- [Research progress of single-incision laparoscopic radical gastrectomy].
- [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
All its trials on ClinicalTrials.gov, any status11
- LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Effects of HIPEC on Postoperative Bowel Motility and Complications
- Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
- TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
- Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
Cancer
Retinoblastoma
视网膜母细胞瘤Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
Cancer
Chordoma
脊索瘤Led 6 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 5.7%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.
- Multi-omics analysis unveils the role of inflammatory cancer-associated fibroblasts in chordoma progression.
- Skull base chordoma and spinal chordoma exhibit consistency in terms of endoplasmic reticulum stress aspects.
- Letter to the Editor Regarding "Hypoxia-inducible Factor-1α (HIF-1α) as a Factor to Predict Prognosis of Spinal Chordoma" by He and Liu.
- The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
- Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)6
- Epidemiological characteristics of 1385 primary sacral tumors in one institution in China.
- Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features.
- A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI.
- Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging.
- miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.
- One-step reconstruction with a 3D-printed, custom-made prosthesis after total en bloc sacrectomy: a technical note.
All its trials on ClinicalTrials.gov, any status1
Cancer
Osteosarcoma
骨肉瘤Led 42 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.9%.
48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingApatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07479732
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingTrilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06714383
Age 14 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05830123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led42
- Evaluating the Impact of Habitat Analysis via IVIM and DCE-MRI on Neoadjuvant Chemotherapy Outcomes in Osteosarcoma Patients: A Preliminary Study.
- T2-weighted magnetic resonance imaging radiogenomic features for the prediction of neoadjuvant chemotherapy response in patients with osteosarcoma.
- Sonographic characteristics of local soft tissue recurrence in primary bone tumor and diagnostic efficacy versus MRI.
- Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.
- Neutrophil elastase promotes low molecular weight cyclin E1 formation to accelerate osteosarcoma proliferation.
- End-to-End Deep Learning Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Patients Using Routine MRI.
- Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets.
- Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.
- CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.
- Magnetic resonance imaging assessment of epiphyseal invasion in paediatric osteosarcoma.
- Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging.
- Direct contact between tumor cells and platelets initiates a FAK-dependent F3/TGF-β positive feedback loop that promotes tumor progression and EMT in osteosarcoma.
- Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.
- Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma.
- The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma.
- Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
- Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.
- Clinical-radiomics models based on plain X-rays for prediction of lung metastasis in patients with osteosarcoma.
- Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
- Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
- Intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging for neoadjuvant chemotherapy response evaluation in patients with osteosarcoma.
- Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.
- Outcomes of Semiknee Replacement in Skeletally Immature Bone Sarcoma Patients.
- Outcomes of Fixed-Hinged Knee Prosthesis for Distal Femoral Osteosarcoma in Skeletally Immature Patients: First Results.
- An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
- Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
- PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
- circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p.
- Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: A systematic review and meta-analysis.
- Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.
- How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?
- Analysis of mechanical complications for patients with extremity sarcoma after biological reconstruction.
- Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3.
- Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment.
- The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma.
- Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China.
- Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
- The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
- RNA-dependent protein kinase is required for interferon-γ-induced autophagy in MG63 osteosarcoma cells.
- Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
- Venous Tumor Thrombus in Primary Bone Sarcomas in the Pelvis: A Clinical and Radiographic Study of 451 Cases.
- Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)31
- Multiple primary tumors: a case report and review of the literature.
- Differentiation of Pelvic Osteosarcoma and Ewing Sarcoma Using Radiomic Analysis Based on T2-Weighted Images and Contrast-Enhanced T1-Weighted Images.
- Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B.
- Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta.
- Lateral malleolus en bloc resection for the distal fibula osteosarcoma based on a new classification and proposed reconstruction choice: Analysis of 6 cases prognosis and literature review.
- The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
- Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
- Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.
- Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma.
- Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
- Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.
- Novel "double-strut" fibula ankle arthrodesis for large tumor-related bone defect of distal tibia.
- [Rasfonin inhibits proliferation and migration of osteosarcoma 143B cells].
- Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis.
- Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.
- Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
- [Effectiveness of free vascularized fibular graft for bone defect after resection of lower limb malignant tumor].
- Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
- Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
- Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono-institutional retrospective study of 115 cases.
- Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
- Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.
- Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy.
- PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
- Rectus femoris branch: An alternative blood supply for a distally based anterolateral thigh flap.
- Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma.
- Surgical treatment of primary malignant tumours of the distal tibia: clinical outcome and reconstructive strategies.
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma.
- Anti-angiogenesis target therapy for advanced osteosarcoma (Review).
- Surgical Treatment of Primary Osteosarcoma of the Sacrum: A Case Series of 26 Patients.
- Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
All its trials on ClinicalTrials.gov, any status23
- Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
- Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
- B7-H3 NIR Imaging for Osteosarcoma Surgery
- Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
- Soluble B7-H3 as a Biomarker for Osteosarcoma
- Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
- Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
- Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
- Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
- Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study
- Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma
- Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS
- Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab
- Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
- Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
- PD-L1 Expression in Advanced Osteosarcoma
- Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum
- Epigenetic Biomarker for Osteosarcoma
- Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
- A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 8 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.5%.
- Open trials as a site
- 0
- led by another institution
23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06748690
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingPrediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
- Phase
- Not given
- Started
- 2022-01
- Registry
- NCT05408897
Age not stated (registered criteria)
Led by Peking University People's HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led8
- Disparities in management guidelines for gastrointestinal stromal tumors: A comparison of recommendations from the Chinese Society of Clinical Oncology, National Comprehensive Cancer Network, and European Society for Medical Oncology.
- Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition).
- CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.
- Morphological, immunohistochemical, and genetic analyses of epithelioid gastrointestinal stromal tumors.
- Hallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis.
- Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.
- Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.
- Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)6
- Safety and efficiency of endoscopic resection versus laparoscopic resection in gastric gastrointestinal stromal tumours: A systematic review and meta-analysis.
- Clinical features of multiple gastrointestinal stromal tumors: A pooling analysis combined with evidence and gap map.
- [Evidence-based standardized diagnosis and treatment of small gastrointestinal stromal tumors].
- [Minimally invasive surgery for gastrointestinal stromal tumors--pursuing the trivial, or striving for perfection].
- Gastrointestinal Stromal Tumors with KIT Mutation Coexisting with Wild-type Gastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1.
- The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors.
All its trials on ClinicalTrials.gov, any status4
- MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
- Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction
- A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid Biopsy
Cancer
Ewing sarcoma
尤文肉瘤Led 7 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 4.3%.
17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingProspective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07725783
Age 10 years to 60 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingWeekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06340204
Age 8 years to 40 years (registered criteria)
Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingA Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06926283
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Hangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.
- Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.
- Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.
- Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
- Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
- Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
- Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status8
- Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
- Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
- Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
- Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
- Irinotecan and Temozolomide for Ewing Sarcoma
- Anlotinib and Irinotecan for Ewing Sarcoma
- A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 19 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.
15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 11
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingKPD Consolidation After ASCT in NDMM Patients
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06879379
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingReal-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07296627
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingRisk Stratification and MRD-driven Maintenance for MM After ASCT
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06697483
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin
- Not yet recruitingASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07320326
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingA Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06369935
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07258511
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an
- RecruitingA Clinical Study of SHR-5421 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07652281
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingMobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT06514508
Age 18 years to 78 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06049290
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- Not yet recruitingA Open-Label Phase in Participants With Multiple Myeloma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07764861
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led19
- Minimal Clonal Plasma Cell Contamination of Peripheral Stem Cell Grafts Has an Adverse Prognostic Impact in Patients with Multiple Myeloma Undergoing Autologous Transplantation.
- Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment.
- Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation:
- The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.
- Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.
- The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050.
- Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China.
- Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes.
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
- Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.
- Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
- Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.
- Combined crystal-storing histiocytosis, light chain proximal tubulopathy, and light chain crystalline podocytopathy in a patient with multiple myeloma: a case report and literature review.
- Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
- Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma.
- The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
- Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
- Extramedullary plasmacytoma of the nasal inferior turbinate: a case report.
Chinese-language papers (not in the count)13
- [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Guidelines for the diagnosis and management of multiple myeloma: 2024 updates].
- [Treatment options for multiple myeloma with renal injury].
- [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].
- [Current status and challenges of immunotherapy for multiple myeloma].
- [A single-center retrospective analysis of 100 consecutive cases treated with lenalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma].
- [A message to the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)-a step further, a level higher].
- [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].
- [Analysis of clinical features of multiple myeloma with t(8;14)(q24;q32)].
- [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
- [Progress in the treatment of multiple myeloma with daratumumab].
- [Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma].
- [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].
All its trials on ClinicalTrials.gov, any status26
- ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
- KPD Consolidation After ASCT in NDMM Patients
- Risk Stratification and MRD-driven Maintenance for MM After ASCT
- A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
- Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
- Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement
- Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
- A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
- A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- A Open-Label Phase in Participants With Multiple Myeloma
- Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
- A Study of Daratumumab
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
- Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 19 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 8.4%.
10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 7
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingCD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07441291
Age 3 years to 79 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingBridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06581081
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingNanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06880913
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingBusulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- Phase
- N/A
- Started
- 2026-11
- Registry
- NCT07919470
Age 14 years to 65 years (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Langfang
- RecruitingAssessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT07244406
Age 3 years to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Phase
- Phase 1
- Started
- 2024-09
- Registry
- NCT06927466
Age 3 years to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led19
- Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance.
- Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
- Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
- CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.
- Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia.
- Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.
- ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
- CAR-T Therapy Followed by Hematopoietic Stem Cell Transplantation Can Improve Survival in Children Relapsed/Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia.
- Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.
- Long-Term Survival and Immune Reconstitution of Donor-Derived Chimeric Antigen Receptor T-Cell Therapy for Childhood Molecular Relapse of B-Cell Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
- Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
- CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia.
- Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor.
- Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.
- The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia.
- Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
- Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.
- Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
- Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status8
- Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
- Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
- A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Safety and Efficacy Evaluation of IM19 CAR-T Cells
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 29 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 7.0%.
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for aplastic anaemia63 hospitals in China for aplastic anaemia
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07586735
Age 40 years to 60 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingPeripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07629947
Age 18 years to 40 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Prediction Model in Pregnant Women With Aplastic Anemia
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07101770
Age 20 years to 50 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led29
- Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia.
- The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.
- The haematopoietic cell transplantation comorbidity index predicts clinical outcomes for severe aplastic anaemia patients after haploidentical haematopoietic stem cell transplantation.
- Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: A CBMTR Registry-based propensity score matching analysis over the last decade.
- The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51-60 Years: A Retrospective Study From the Chinese
- Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.
- TGF-β inhibition restores hematopoiesis and immune balance via bone marrow EPCs in aplastic anemia.
- G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.
- Ovarian tissue cryopreservation after graft failure of allogeneic hematopoietic stem cell transplantation: first report and literature review.
- The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese Blood and Marrow Transplant Registry group.
- BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling.
- Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia.
- Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation.
- Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anem
- Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients.
- Repair of dysfunctional bone marrow endothelial cells alleviates aplastic anemia.
- Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia.
- Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia.
- Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
- Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation.
- A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity.
- The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia.
- Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study.
- The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents.
- Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study.
- Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.
- Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges.
- The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia.
- Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings.
Chinese-language papers (not in the count)5
- [Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].
- [Severe cardiotoxic characteristics associated with allogeneic hematopoietic stem cell transplantation preconditioning in patients with aplastic anemia].
- [Causes and characteristics of pre-engraftment mortality after allogeneic hematopoietic stem cell transplantation].
- [Safety and survival analysis of haplo-identical hematopoietic stem cell transplantation in patients with severe aplastic anemia who had previous failure to antithymoglobulin treatment].
- [Erythrocytosis after hematopoietic stem cell transplantation: report of 3 cases and literature review].
All its trials on ClinicalTrials.gov, any status5
- A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
- Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
- A Prediction Model in Pregnant Women With Aplastic Anemia
- The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
- Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 7 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.8%.
11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingHemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07905066
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Clinical manifestations and outcomes of EBV-related secondary hemophagocytic lymphohistiocytosis.
- Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.
- Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort.
- COX Regression Analysis and Mortality Risk Prediction Model of 85 Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.
- A predictive model for identifying secondary underlying diseases of hemophagocytic lymphohistiocytosis.
- Hemophagocytic Lymphohistiocytosis Secondary to Juvenile Myelomonocytic Leukemia: A Case Report and Review of the Literature.
- Hemophagocytic syndrome and neurological involvement in a case of intravascular large B-cell lymphoma.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status3
- Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
More papers found outside PubMed (not counted)2
Blood disorders
Haemophilia A
血友病 A15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLongitudinal Cohort of Thrombosis and Hemostasis Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06727669
Age not stated (registered criteria)
Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07416526
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 4 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 6.2%.
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLongitudinal Cohort of Thrombosis and Hemostasis Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06727669
Age not stated (registered criteria)
Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou
- RecruitingBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06794008
Age 18 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Thrombotic thrombocytopenic purpura following allogeneic hematopoietic stem cell transplantation: a rare but fatal complication.
- Experience in emergency management of first-episode immune thrombotic thrombocytopenic purpura over the past 21 years: a single-center retrospective study.
- Clinical characteristics and treatment response of patients with SLE complicated with thrombotic thrombocytopenic purpura.
- Comparison of clinical characteristics of first-episode thrombotic thrombocytopenic purpura and TTP-like syndrome: a retrospective cohort study in a level I hematology center in China.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Fanconi anaemia
范可尼贫血Led 2 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 2.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Beijing for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anem
- Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingEfficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07809724
Age 18 years to 74 years (registered criteria)
Led by Peking University People's HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 12 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 4.9%.
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06794008
Age 18 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Primary intraosseous Rosai-Dorfman disease: Clinicopathological features and an assessment of a possible relationship with IgG4-related disease.
- Clinical characterization of malignant lymphoma mimicking IgG4-related disease.
- Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.
- Clinical profiles differ in IgG4-related disease with and without allergy: a large case-control study in China.
- Immune phenotype changes in IgG4-related disease: CD161 + Treg and Foxp3 + Treg.
- Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.
- IL-7 Promotes the Expansion of Circulating CD28- Cytotoxic T Lymphocytes in Patients With IgG4-Related Disease via the JAK Signaling.
- Characteristics of IgG4-related disease complicated with allergic rhinitis or chronic rhinosinusitis: a large cross-sectional cohort study.
- Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China.
- Needle biopsy compared with surgical biopsy: pitfalls of small biopsy in histologial diagnosis of IgG4-related disease.
- Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study.
- Disparities between IgG4-related kidney disease and extrarenal IgG4-related disease in a case-control study based on 450 patients.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)5
- POS1249 CIRCULATING GRANZYME K+ CD8+ T CELLS UNDERLYING THE MECHANISMS OF IgG4-RELATED DISEASE
- POS0922 DIFFERENTIAL DIAGNOSIS OF FOCAL IMMUNOGLOBULIN G4-RELATED SIALADENITIS AND BENIGN SALIVARY MASSES: THE VALUE OF CONTRAST-ENHANCED ULTRASOUND
- Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity
- AB0758 CLINICAL PROFILES DIFFER IN IGG4-RELATED DISEASE WITH AND WITHOUT ATOPY: A LARGE CASE-CONTROL STUDY IN CHINA
- POS1384 DIFFERENT CLINICAL CHARACTERISTICS OF IGG4-RRD PATIENTS AND NON-IGG4-RRD PATIENTS: A LARGE CHINESE COHORT STUDY
Other diseases
Myasthenia gravis
重症肌无力Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Single-Cell Immune Profiling Reveals Neutrophils Promote Myasthenia Gravis Exacerbation Through BAFF Secretion.
- Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab.
- Risk factors of prolonged ventilation after thymectomy in thymoma myasthenia gravis patients.
Other diseases
Takayasu arteritis
大动脉炎Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status2
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: a case control study.
- Respiratory infection risk in primary Sjögren's syndrome complicated with interstitial lung disease: a retrospective study.
- Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Behçet disease
白塞病Led 5 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 2.0%.
24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06794008
Age 18 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
- RecruitingAutoInflammatory Disease Alliance Registry (AIDA)
- Phase
- Not given
- Started
- 2020-08
- Registry
- NCT05200715
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.
- Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'.
- Comparison of different onset ages in patients with Behcet's disease.
- Comment on: Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China: reply.
- Refractory Behçet's disease treated with low-dose interleukin-2: A case report.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)5
- [Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report].
- Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet's Disease.
- A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.
- [Capsule endoscopy for Behcet's disease-treatment: five cases reports].
- Outcomes of surgery for patients with Behcet's disease causing aortic pseudoaneurysm: a shift from open surgery to endovascular repair.
All its trials on ClinicalTrials.gov, any status9
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.
- Ivarmacitinib for Refractory Behcet's Syndrome
- Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
- Upadacitinib for Refractory Behcet's Syndrome
- Low-dose IL-2 Treatment on Behcet's Disease
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- AutoInflammatory Disease Alliance Registry (AIDA)
- A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status6
- A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Beijing for Gaucher disease41 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Osteogenesis imperfecta
成骨不全症Led 2 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 2.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Beijing for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 7 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 2.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led7
- Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis.
- Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis.
- The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models.
- Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.
- Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.
- Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.
- Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07387549
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Beijing for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other linked evidence
Getting in touch
Name card to show staff or a driver
北京大学人民医院
Peking University People's Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
a Peking University People's Hospital; China Peking University People's Hospital; PKUPH